title: Ingestion of low dose pyroglutamyl leucine improves dextran sulfate sodium-induced colitis and intestinal microbiota in mice.
abstract: Inflammatory bowel diseases (IBD) are based on chronic inflammation in the gastrointestinal tract. We previously found anti-inflammatory peptide pyroGlu-Leu in the enzymatic hydrolysate of wheat gluten. The objective of present study is to elucidate improvement of colitis by oral administration of pyroGlu-Leu in an animal model. Acute colitis was induced by dextran sulfate sodium (DSS), and various concentrations of pyroGlu-Leu were administrated by oral gavage for 7 days. A dose of 0.1 mg/kg body weight/day showed the most significant improvement. The pyroGlu-Leu concentration was significantly increased 24 h after oral administration both in the small intestine and the colon compared with the baseline. It was 20-fold higher in the small intestine than the colon. Administration of pyroGlu-Leu normalized population of Bacteroidetes and Firmicutes in the colon. These results indicate that pyroGlu-Leu has a potential therapeutic effect against IBD at a practical dose.
authors: Division of Applied Life Sciences, Graduate School of Life and Environmental Sciences, Kyoto Prefectural University , Shimogamo, Kyoto, 606 8522, Japan.
authors: Sayori
authors: S
authors: Wada
authors: Kenji
authors: K
authors: Sato
authors: Ryoko
authors: R
authors: Ohta
authors: Eri
authors: E
authors: Wada
authors: Yukiho
authors: Y
authors: Bou
authors: Miki
authors: M
authors: Fujiwara
authors: Tamami
authors: T
authors: Kiyono
authors: Eun Young
authors: EY
authors: Park
authors: Wataru
authors: W
authors: Aoi
authors: Tomohisa
authors: T
authors: Takagi
authors: Yuji
authors: Y
authors: Naito
authors: Toshikazu
authors: T
authors: Yoshikawa
mesh_terms: D000818:Animals; D000893:Anti-Inflammatory Agents / Q000008:administration & dosage; D003092:Colitis / Q000139:chemically induced / Q000188:drug therapy* / Q000382:microbiology; D016264:Dextran Sulfate / Q000009:adverse effects; D004151:Dipeptides / Q000008:administration & dosage*; D004195:Disease Models, Animal; D006801:Humans; D007422:Intestines / Q000187:drug effects / Q000382:microbiology*; D008297:Male; D051379:Mice; D008810:Mice, Inbred C57BL; D064307:Microbiota / Q000187:drug effects*; D011761:Pyrrolidonecarboxylic Acid / Q000008:administration & dosage / Q000031:analogs & derivatives*
chemical_list: D000893:Anti-Inflammatory Agents; D004151:Dipeptides; C041765:pyroglutamylleucine; D016264:Dextran Sulfate; D011761:Pyrrolidonecarboxylic Acid